- Stocks
- Pharma & Healthcare
- Healthcare Global Enterprises
Healthcare Global Enterprises share price
NSE: HCGPharma & HealthcareMedical Care Facilities
Healthcare Global Enterprises at a glance
Healthcare Global Enterprises (NSE: HCG) closed at ₹552.00 on 22 Oct 2026, up 0.60% on the day. With a market capitalisation of ₹8,241 Cr, it ranks 604th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Medical Care Facilities.
Its return on equity was 1.0% in FY26. Over the past year the share price has fallen 19.8%. Its 52-week range is ₹513.30 (30 Mar 2026) to ₹799.70 (24 Oct 2025); the last close is 31.0% below the high. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹695 Cr (+13.4% year on year) and net profit ₹16 Cr (+193.0%), on a consolidated basis. Promoters held 64.21% of the company as of 30 Jun 2026; 5.17% of promoter shares were pledged.
Key numbers
- Market cap
- ₹8,241 CrRank 604 on NSE
- Price to book
- 5.88×FY26
- EPS (TTM)
- ₹1.55to Q1 FY27
- ROE
- 1.0%FY26
- ROCE
- 8.5%FY26
- Debt to equity
- 0.68FY26
- Net profit margin
- 0.8%FY26
- Book value / share
- ₹89.21FY26
- 52-week high
- ₹799.7024 Oct 2025
- 52-week low
- ₹513.3030 Mar 2026
- 1-year return
- −19.8%
- RSI (14-day)
- 25.8
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | +0.60% | −6.1% | −21.1% | −17.6% | −19.8% |
Healthcare Global Enterprises quarterly results
| Quarter | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹554 Cr | ₹559 Cr | ₹585 Cr | ₹613 Cr | ₹647 Cr | ₹633 Cr | ₹652 Cr | ₹695 Cr |
| Revenue YoY | +13.7% | +18.9% | +18.3% | +16.7% | +16.9% | +13.3% | +11.5% | +13.4% |
| Net profit | ₹21 Cr | ₹7 Cr | ₹7 Cr | ₹5 Cr | ₹20 Cr | −₹8 Cr | ₹4 Cr | ₹16 Cr |
| Net profit YoY | +91.9% | +99.1% | −70.7% | −61.1% | −1.7% | −214.6% | −48.7% | +193.0% |
| Net margin | 3.7% | 1.2% | 1.2% | 0.9% | 3.1% | −1.2% | 0.5% | 2.2% |
| EPS | ₹1.29 | ₹0.50 | ₹0.53 | ₹0.34 | ₹1.16 | −₹0.68 | ₹0.15 | ₹0.92 |
Healthcare Global Enterprises financials
| Item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Revenue | ₹1,013 Cr | ₹1,398 Cr | ₹1,691 Cr | ₹1,908 Cr | ₹2,223 Cr | — |
| Operating profit | −₹135 Cr | −₹5 Cr | ₹45 Cr | ₹63 Cr | ₹56 Cr | — |
| Net profit | −₹221 Cr | ₹40 Cr | ₹18 Cr | ₹41 Cr | ₹48 Cr | — |
| EPS (₹) | −₹17.00 | ₹4.00 | ₹2.00 | ₹3.00 | ₹3.00 | — |
| Cash from operations | ₹121 Cr | ₹220 Cr | ₹252 Cr | ₹285 Cr | ₹317 Cr | — |
| Total debt | ₹346 Cr | ₹363 Cr | ₹362 Cr | ₹485 Cr | ₹605 Cr | ₹599 Cr |
| Shareholders' equity | ₹697 Cr | ₹870 Cr | ₹861 Cr | ₹826 Cr | ₹922 Cr | ₹1,332 Cr |
Healthcare Global Enterprises shareholding pattern
| Holder | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 27 Mar 2026 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 62.46% | 63.78% | 63.77% | 64.21% | 64.21% | 64.21% |
| Foreign institutions | 2.16% | 3.59% | 3.22% | 2.71% | 2.75% | 2.74% |
| Domestic institutions | 13.22% | 18.36% | 18.30% | 18.89% | 18.91% | 19.20% |
| Non-institutions | 22.16% | 14.27% | 14.71% | 14.18% | 14.13% | 13.85% |
| Promoter shares pledged | 88.00% | 85.23% | 85.23% | 79.94% | 5.17% | 5.17% |
Healthcare Global Enterprises vs peers
The listed Pharma & Healthcare companies nearest to Healthcare Global Enterprises by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| VIYASHViyash Scientific | ₹214.90 | −0.05% | +3.1% | ₹9,388 Cr | 53.6 | — |
| STARStrides Pharma Science | ₹1,017.30 | −1.23% | +27.8% | ₹9,377 Cr | 16.9 | — |
| YATHARTHYatharth Hospital & Trauma Care Services | ₹932.10 | +1.22% | +14.4% | ₹8,981 Cr | 51.2 | — |
| HCGHealthcare Global Enterprises | ₹552.00 | +0.60% | −19.8% | ₹8,241 Cr | — | — |
| SUVENSuven Life Sciences | ₹276.60 | −0.31% | +39.7% | ₹7,816 Cr | — | — |
| SANOFICONRSanofi Consumer Healthcare India | ₹3,325.80 | −0.28% | −29.8% | ₹7,660 Cr | 29.7 | — |
| AARTIPHARMAarti Pharmalabs | ₹838.00 | −0.91% | +1.5% | ₹7,599 Cr | 43.6 | — |
Ask anything about Healthcare Global Enterprises
Pivot answers on the live chart with evidence you can check, and tests strategies against HCG's own history. Try: “Why has HCG moved over the last three months?” · “Backtest a 50-day moving-average crossover on HCG over five years” · “Compare HCG with VIYASH on margins and valuation”
Frequently asked questions about Healthcare Global Enterprises
What is the share price of Healthcare Global Enterprises today?
Healthcare Global Enterprises (NSE: HCG) last closed at ₹552.00 on 22 Oct 2026. Its 52-week high is ₹799.70 and its 52-week low is ₹513.30.
What is the market cap of Healthcare Global Enterprises?
Healthcare Global Enterprises' market capitalisation is ₹8,241 Cr (₹8,241 Cr) at the 22 Oct 2026 close, ranking 604th among the NSE companies Pivot tracks.
What is the ROE and ROCE of Healthcare Global Enterprises?
Return on equity was 1.0% in FY26 and return on capital employed was 8.5% in FY26 (consolidated figures).
Is Healthcare Global Enterprises a debt-free company?
No. Healthcare Global Enterprises' debt-to-equity ratio was 0.68 in FY26, with total debt of ₹599 Cr.
What were Healthcare Global Enterprises' latest quarterly results?
For Q1 FY27 (quarter ended 30 Jun 2026), Healthcare Global Enterprises reported revenue of ₹695 Cr, +13.4% year on year, and net profit of ₹16 Cr, +193.0% year on year.
How has Healthcare Global Enterprises stock performed over the last year?
Healthcare Global Enterprises' share price has fallen 19.8% over the past year, −17.6% over three months and −21.1% over one month, to the 22 Oct 2026 close.
What is the shareholding pattern of Healthcare Global Enterprises?
As of 30 Jun 2026: promoters 64.21%, foreign institutions 2.74%, domestic institutions 19.20%, non-institutions 13.85%. 5.17% of promoter shares were pledged.
Who are Healthcare Global Enterprises' competitors?
The listed Pharma & Healthcare companies closest to Healthcare Global Enterprises by market cap are Viyash Scientific, Strides Pharma Science, Yatharth Hospital & Trauma Care Services, Suven Life Sciences, Sanofi Consumer Healthcare India and Aarti Pharmalabs.
Is Healthcare Global Enterprises a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Healthcare Global Enterprises' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on HCG against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with H · all NSE stocks · this page as text